Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with intravitreal antiVEGF (moderate certainty).
Intravitreal fluocinolone acetonide implant 0.19 mg probably leads to higher use of IOP‐lowering medications ‐ 24 months compared with sham (moderate certainty).
It is very uncertain whether intravitreal triamcinolone acetonide injection 4 mg changes use of IOP‐lowering medications ‐ 24 months compared with sham (very low certainty).
Intravitreal triamcinolone acetonide injection 4 mg probably leads to higher use of IOP‐lowering medications ‐ 9 to 24 months compared with macular laser (moderate certainty).
Intravitreal dexamethasone implant 0.7 mg probably leads to higher use of IOP‐lowering medications ‐ 36 months compared with sham (moderate certainty).